Camblong Jurgi sold $118K of SOPH
Camblong Jurgi (Executive Chairman) sold 22,486 shares of SOPHiA GENETICS SA (SOPH) at $5.26 ($0.12M total) on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor for follow-on insider activity, but this specific filing mainly updates ownership records rather than providing new company fundamentals.
Market read
A disclosed insider sale under a 10b5-1 plan is typically low-signal for fundamentals, with at most a minor sentiment effect.
What to watch
The sale size (~$118K) is modest relative to typical market capitalization, and the disclosure does not include any new operational or financial guidance.
Background
The article is an SEC Form 4 insider transaction: Camblong Jurgi (Executive Chairman) executed an open-market sale under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Executive Chairman Camblong Jurgi sold 22,486 shares of SOPHiA GENETICS at $5.2550/share for ~$118.2K under a 10b5-1 plan.
Likely limited near-term impact; any effect should be small and short-lived unless followed by additional disclosures.
The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider liquidity activity.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative signal.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider sale disclosure; ticker SOPH.
- insiderCamblong Jurgi
Executive Chairman who sold 22,486 shares at $5.2550/share on 2026-07-06.
